6,000 Shares in AbbVie Inc. (NYSE:ABBV) Purchased by Dymon Asia Capital Singapore PTE. LTD.

Dymon Asia Capital Singapore PTE. LTD. bought a new position in AbbVie Inc. (NYSE:ABBV) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 6,000 shares of the company’s stock, valued at approximately $1,066,000. AbbVie accounts for approximately 0.2% of Dymon Asia Capital Singapore PTE. LTD.’s portfolio, making the stock its 22nd largest holding.

A number of other institutional investors also recently modified their holdings of ABBV. Argent Trust Co boosted its stake in AbbVie by 0.3% in the 4th quarter. Argent Trust Co now owns 200,426 shares of the company’s stock worth $35,616,000 after purchasing an additional 540 shares during the period. Accredited Investors Inc. grew its position in shares of AbbVie by 2.0% during the 4th quarter. Accredited Investors Inc. now owns 8,091 shares of the company’s stock valued at $1,438,000 after purchasing an additional 159 shares in the last quarter. EnRich Financial Partners LLC increased its holdings in shares of AbbVie by 196.4% in the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock worth $29,000 after purchasing an additional 110 shares during the period. Kennedy Capital Management LLC boosted its stake in AbbVie by 13.3% during the fourth quarter. Kennedy Capital Management LLC now owns 108,138 shares of the company’s stock valued at $19,216,000 after buying an additional 12,675 shares during the period. Finally, Treasurer of the State of North Carolina grew its position in AbbVie by 1.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 891,351 shares of the company’s stock worth $158,393,000 after buying an additional 13,980 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ABBV. Bank of America lifted their price target on AbbVie from $200.00 to $223.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. BMO Capital Markets raised their price objective on AbbVie from $208.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, February 3rd. Citigroup increased their price target on shares of AbbVie from $205.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Raymond James restated an “outperform” rating and issued a $220.00 price objective (up from $218.00) on shares of AbbVie in a report on Monday, February 3rd. Finally, Piper Sandler Companies reaffirmed an “overweight” rating and issued a $220.00 price objective on shares of AbbVie in a research note on Tuesday, December 17th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $210.71.

AbbVie Trading Down 3.4 %

ABBV opened at $173.80 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $218.66. The stock has a market cap of $307.44 billion, a PE ratio of 72.42, a PEG ratio of 1.62 and a beta of 0.55. The business has a 50 day moving average of $200.47 and a 200-day moving average of $188.60.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period in the previous year, the business posted $2.79 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be issued a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.77%. The ex-dividend date is Tuesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 273.33%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 5,778 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the sale, the executive vice president now directly owns 22,381 shares of the company’s stock, valued at approximately $4,429,199.90. The trade was a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the transaction, the executive vice president now owns 53,234 shares of the company’s stock, valued at $11,183,398.72. The trade was a 52.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 113,471 shares of company stock valued at $23,426,451. Corporate insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.